Department of Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands.
Int Rev Neurobiol. 2011;101:351-74. doi: 10.1016/B978-0-12-387718-5.00014-6.
There is a major unmet clinical need for molecular blood-based biomarkers in studies of major psychiatric disorders. Thus far, identification of such biomarkers has been sparse, most likely due to the fact that this is reliant on long-standing diagnostic concepts used in psychiatry, which are notoriously heterogeneous. Also, identification of biomarkers for a syndrome that has already been categorized based on clinical phenomenology is not useful in the clinic. This chapter describes the need for innovative approaches for identification of biomarkers which can been used to classify at-risk patients such as youngsters with prodromal symptoms for psychosis and existing patients who are likely to progress to more severe states. The authors argued for the use of broader categories of related patients and to deconstruct the traditional diagnoses in favor of molecular biomarker profiles.
在研究主要精神疾病时，临床上非常需要分子血液生物标志物。到目前为止，这种生物标志物的识别仍然很少，这很可能是因为它依赖于精神病学中长期使用的诊断概念，而这些概念众所周知是异质的。此外，对于已经基于临床表型学进行分类的综合征，识别生物标志物在临床上并没有用处。本章描述了需要创新的方法来识别生物标志物，以便对有风险的患者进行分类，例如有精神病前驱症状的年轻人和可能进展为更严重状态的现有患者。作者主张使用更广泛的相关患者类别，并打破传统诊断，转而采用分子生物标志物谱。
